These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
216 related items for PubMed ID: 34306830
1. Effect of genetic background on the evolution of Vancomycin-Intermediate Staphylococcus aureus (VISA). Su M, Davis MH, Peterson J, Solis-Lemus C, Satola SW, Read TD. PeerJ; 2021; 9():e11764. PubMed ID: 34306830 [Abstract] [Full Text] [Related]
2. Contribution of selected gene mutations to resistance in clinical isolates of vancomycin-intermediate Staphylococcus aureus. Hafer C, Lin Y, Kornblum J, Lowy FD, Uhlemann AC. Antimicrob Agents Chemother; 2012 Nov; 56(11):5845-51. PubMed ID: 22948864 [Abstract] [Full Text] [Related]
4. Novel Mutation Sites in the Development of Vancomycin- Intermediate Resistance in Staphylococcus aureus. Wang Y, Li X, Jiang L, Han W, Xie X, Jin Y, He X, Wu R. Front Microbiol; 2016 Nov; 7():2163. PubMed ID: 28119680 [Abstract] [Full Text] [Related]
6. Genetic changes associated with glycopeptide resistance in Staphylococcus aureus: predominance of amino acid substitutions in YvqF/VraSR. Kato Y, Suzuki T, Ida T, Maebashi K. J Antimicrob Chemother; 2010 Jan; 65(1):37-45. PubMed ID: 19889788 [Abstract] [Full Text] [Related]
7. Generation of a vancomycin-intermediate Staphylococcus aureus (VISA) strain by two amino acid exchanges in VraS. Berscheid A, François P, Strittmatter A, Gottschalk G, Schrenzel J, Sass P, Bierbaum G. J Antimicrob Chemother; 2014 Dec; 69(12):3190-8. PubMed ID: 25103491 [Abstract] [Full Text] [Related]
8. A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin. Passalacqua KD, Satola SW, Crispell EK, Read TD. Antimicrob Agents Chemother; 2012 Oct; 56(10):5212-23. PubMed ID: 22850507 [Abstract] [Full Text] [Related]
9. The effect of subinhibitory concentration of chlorhexidine on the evolution of vancomycin-intermediate Staphylococcus aureus and the induction of mutations in walKR and vraTSR systems. Baseri N, Najar-Peerayeh S, Bakhshi B. Infect Genet Evol; 2021 Jan; 87():104628. PubMed ID: 33171303 [Abstract] [Full Text] [Related]
10. A mutation of RNA polymerase β' subunit (RpoC) converts heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) into "slow VISA". Matsuo M, Hishinuma T, Katayama Y, Hiramatsu K. Antimicrob Agents Chemother; 2015 Jul; 59(7):4215-25. PubMed ID: 25941225 [Abstract] [Full Text] [Related]
11. Mutation of RNA polymerase beta subunit (rpoB) promotes hVISA-to-VISA phenotypic conversion of strain Mu3. Matsuo M, Hishinuma T, Katayama Y, Cui L, Kapi M, Hiramatsu K. Antimicrob Agents Chemother; 2011 Sep; 55(9):4188-95. PubMed ID: 21746940 [Abstract] [Full Text] [Related]
12. Comprehensive identification of mutations responsible for heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA)-to-VISA conversion in laboratory-generated VISA strains derived from hVISA clinical strain Mu3. Matsuo M, Cui L, Kim J, Hiramatsu K. Antimicrob Agents Chemother; 2013 Dec; 57(12):5843-53. PubMed ID: 24018261 [Abstract] [Full Text] [Related]
13. Role of stop codons in development and loss of vancomycin non-susceptibility in methicillin-resistant Staphylococcus aureus. Doddangoudar VC, O'Donoghue MM, Chong EY, Tsang DN, Boost MV. J Antimicrob Chemother; 2012 Sep; 67(9):2101-6. PubMed ID: 22643192 [Abstract] [Full Text] [Related]
14. Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia. Howden BP, Smith DJ, Mansell A, Johnson PD, Ward PB, Stinear TP, Davies JK. BMC Microbiol; 2008 Feb 27; 8():39. PubMed ID: 18304359 [Abstract] [Full Text] [Related]
15. Prevalence of vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA among methicillin-resistant S. aureus with high vancomycin minimal inhibitory concentrations in Taiwan: A multicenter surveillance study, 2012-2013. Huang SH, Chen YC, Chuang YC, Chiu SK, Fung CP, Lu PL, Wang LS, Wu TL, Wang JT. J Microbiol Immunol Infect; 2016 Oct 27; 49(5):701-707. PubMed ID: 26320398 [Abstract] [Full Text] [Related]
16. The Prevalence of Vancomycin-Intermediate Staphylococcus aureus and Heterogeneous VISA Among Methicillin-Resistant Strains Isolated from Pediatric Population in a Turkish University Hospital. Mirza HC, Sancak B, Gür D. Microb Drug Resist; 2015 Oct 27; 21(5):537-44. PubMed ID: 25919019 [Abstract] [Full Text] [Related]
17. Exposure of Staphylococcus aureus to subinhibitory concentrations of β-lactam antibiotics induces heterogeneous vancomycin-intermediate Staphylococcus aureus. Roch M, Clair P, Renzoni A, Reverdy ME, Dauwalder O, Bes M, Martra A, Freydière AM, Laurent F, Reix P, Dumitrescu O, Vandenesch F. Antimicrob Agents Chemother; 2014 Sep 27; 58(9):5306-14. PubMed ID: 24957836 [Abstract] [Full Text] [Related]
18. walK and clpP mutations confer reduced vancomycin susceptibility in Staphylococcus aureus. Shoji M, Cui L, Iizuka R, Komoto A, Neoh HM, Watanabe Y, Hishinuma T, Hiramatsu K. Antimicrob Agents Chemother; 2011 Aug 27; 55(8):3870-81. PubMed ID: 21628539 [Abstract] [Full Text] [Related]
19. Evaluation of vancomycin in combination with piperacillin-tazobactam or oxacillin against clinical methicillin-resistant Staphylococcus aureus Isolates and vancomycin-intermediate S. aureus isolates in vitro. Dilworth TJ, Sliwinski J, Ryan K, Dodd M, Mercier RC. Antimicrob Agents Chemother; 2014 Aug 27; 58(2):1028-33. PubMed ID: 24277036 [Abstract] [Full Text] [Related]
20. Reduced susceptibility to vancomycin in isogenic Staphylococcus aureus strains of sequence type 59: tracking evolution and identifying mutations by whole-genome sequencing. Chen CJ, Lin MH, Shu JC, Lu JJ. J Antimicrob Chemother; 2014 Feb 27; 69(2):349-54. PubMed ID: 24092658 [Abstract] [Full Text] [Related] Page: [Next] [New Search]